BeiGene announced that the China National Medical Products Administration, or NMPA, granted approval for the company’s PD-1 inhibitor, tislelizumab, in combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BGNE:
- Immix Biopharma doses first two patients in Phase 1b/2a combination trial
- BeiGene price target raised to $350 from $290 at Guggenheim
- BeiGene announces FDA approval of Brukinsa for CLL
- BeiGene announces MHRA granted marketing authorization for BRUKINSA
- BeiGene announces expansion of coverage on China’s NRDL
